[go: up one dir, main page]

MX9710399A - Citocina que induce apoptosis. - Google Patents

Citocina que induce apoptosis.

Info

Publication number
MX9710399A
MX9710399A MX9710399A MX9710399A MX9710399A MX 9710399 A MX9710399 A MX 9710399A MX 9710399 A MX9710399 A MX 9710399A MX 9710399 A MX9710399 A MX 9710399A MX 9710399 A MX9710399 A MX 9710399A
Authority
MX
Mexico
Prior art keywords
trail
induces apoptosis
cells
cytokine
antibodies
Prior art date
Application number
MX9710399A
Other languages
English (en)
Other versions
MXPA97010399A (es
Inventor
Steven R Wiley
Raymond G Goodwin
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27052201&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9710399(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of MX9710399A publication Critical patent/MX9710399A/es
Publication of MXPA97010399A publication Critical patent/MXPA97010399A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L27/00—Modulated-carrier systems
    • H04L27/18—Phase-modulated carrier systems, i.e. using phase-shift keying
    • H04L27/22—Demodulator circuits; Receiver circuits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una nueva citocina designada TRAIL que induce apoptosis de ciertas células objetivo, incluyendo células de cancer y células viralmente infectadas. Las secuencias de DNA aisladas que codifican TRAIL son descritas, junto con los vectores de expresion y células huésped transformadas utiles en producir polipéptidos TRAIL. También se proporcionan los anticuerpos que específicamente ligan TRAil.
MXPA/A/1997/010399A 1995-06-29 1997-12-18 Citocina que induce apoptosis MXPA97010399A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US496632 1990-03-21
US49663295A 1995-06-29 1995-06-29
US54836895A 1995-11-01 1995-11-01
US548368 1995-11-01
PCT/US1996/010895 WO1997001633A1 (en) 1995-06-29 1996-06-25 Cytokine that induces apoptosis

Publications (2)

Publication Number Publication Date
MX9710399A true MX9710399A (es) 1998-03-31
MXPA97010399A MXPA97010399A (es) 1998-10-15

Family

ID=

Also Published As

Publication number Publication date
CA2225378A1 (en) 1997-01-16
PT1666591E (pt) 2011-06-01
AU708239B2 (en) 1999-07-29
EP1666591A1 (en) 2006-06-07
DK1666591T3 (da) 2011-05-23
EP0835305A1 (en) 1998-04-15
IL184699A (en) 2011-11-30
JPH11508445A (ja) 1999-07-27
DE69638346D1 (de) 2011-05-05
ATE503013T1 (de) 2011-04-15
HK1092836A1 (en) 2007-02-16
IL122408A0 (en) 1998-06-15
HK1010215A1 (en) 1999-06-17
NO976045L (no) 1998-03-02
IL122408A (en) 2008-03-20
DE69635480D1 (de) 2005-12-29
ES2253753T3 (es) 2006-06-01
US5763223A (en) 1998-06-09
NO976045D0 (no) 1997-12-22
NO321707B1 (no) 2006-06-26
ES2362191T3 (es) 2011-06-29
EP0835305A4 (en) 2002-02-06
AU6340796A (en) 1997-01-30
JP4435304B2 (ja) 2010-03-17
KR100510234B1 (ko) 2005-11-25
KR101004174B1 (ko) 2010-12-24
IL184699A0 (en) 2007-12-03
DE69635480T2 (de) 2006-08-17
KR20050085914A (ko) 2005-08-29
IL149261A0 (en) 2002-11-10
IL149261A (en) 2006-09-05
IL190068A0 (en) 2008-08-07
EP0835305B1 (en) 2005-11-23
ATE310813T1 (de) 2005-12-15
EP1666591B1 (en) 2011-03-23
NZ311982A (en) 1999-08-30
DK0835305T3 (da) 2006-02-13
WO1997001633A1 (en) 1997-01-16
KR19990028264A (ko) 1999-04-15
CA2225378C (en) 2012-04-17

Similar Documents

Publication Publication Date Title
EP0835305A4 (en) APOPTOSIS INDUCING CYTOKINE
AU4639396A (en) Cytokine designated lerk-7
NZ501340A (en) Redirection of cellular immune response by administering protein-tyrosine kinase chimeras
DK1009832T3 (da) Cytokin betegnet LERK-6
IL193919A0 (en) DcR3 POLYPEPTIDE A TNFR HOMOLOG
PT757717E (pt) Vacinas de papilomavirus
AU3431497A (en) DNA immunization against Chlaymdia infection
EP0739350A4 (en) FAS ANTI-BINDING LIGAND
EP1007537A4 (en) RECEPTOR PROTEIN DESIGNATED BY 2F1
ATE386101T1 (de) Expressionsplasmide, durch einen osmb promoter reguliert
ES8609475A1 (es) Procedimiento para preparar peptidos de interferon
MY125980A (en) Highly purified cytokine activating factor and methods of use
MX9702341A (es) Citoquina designada lerk-6.
NZ304789A (en) Genes encoding lymphocyte interferon regulatory factory (lsirf) polypeptides that are transcription factors and specific antibodies to them
FI971086A7 (fi) Kinaasia sitova proteiini ja sen käyttö
DE59610098D1 (de) Protein mit anti-tumorwirkung
MX9700213A (es) Citocina novedosa designada como lerk-5.
WO2002020567A3 (en) Mammalian cystatin-8 and its use to inhibit cancer procoagulant protein
SU1515698A1 (ru) Рекомбинантная плазмидная днк, кодирующая синтез hbs ag вируса гепатита b, и штамм вируса осповакцины - продуцент hbs ag вируса гепатита b